Search results for "Personalized"

showing 10 items of 165 documents

Plasma cell-free DNA in diagnostic KRAS mutation testing

2015

Epidermaalisen kasvutekijän reseptorin (EGFR) monoklonaalisia vasta-aineita (mAb) käytetään apuna metastaattisen kolorektaalisyövän (mCRC) hoidossa. Aktivoivat mutaatiot KRAS- ja NRAS-onkogeeneissä tekevät syöpäsolut vastustuskykyisiksi anti-EGFR-vasta-aineille, ja tästä syystä tuumorit tulee genotyypittää ennen hoidon aloittamista. Kudosbiopsian ottaminen on kuitenkin invasiivinen toimenpide, eikä näyte välttämättä edusta kattavasti syövän kaikkien solupopulaatioiden geneettisiä muutoksia. Verenkierron solunulkoisen DNA:n (cfDNA) on havaittu sisältävän maligneista soluista lähtöisin olevia onkogeenisiä mutaatioita, ja se voi olla hyvä vaihtoehtoinen tuumoriperäisen DNA:n lähde. Kehitimme j…

KRAS mutation testingpyrosequencinggeenitmetastatic colorectal cancerE-ice-COLD-PCRpersonalized medicinesuolistosyövätmutaatiothoito
researchProduct

Systematic literature review of E-learning capabilities to enhance organizational learning

2021

AbstractE-learning systems are receiving ever increasing attention in academia, business and public administration. Major crises, like the pandemic, highlight the tremendous importance of the appropriate development of e-learning systems and its adoption and processes in organizations. Managers and employees who need efficient forms of training and learning flow within organizations do not have to gather in one place at the same time or to travel far away to attend courses. Contemporary affordances of e-learning systems allow users to perform different jobs or tasks for training courses according to their own scheduling, as well as to collaborate and share knowledge and experiences that res…

Knowledge managementComputer Networks and CommunicationsComputer scienceE-learning (theory)Big dataLearning analyticsPersonalized learningE-learningArticleTheoretical Computer ScienceLearning environmentsEmpirical research0502 economics and businessLiterature reviewbusiness.industry05 social sciencesOrganizational learning050301 educationVDP::Matematikk og Naturvitenskap: 400Systematic reviewCategorizationOrganizational learningbusiness0503 education050203 business & managementSoftwareInformation Systems
researchProduct

Technology-Enhanced Organizational Learning: A Systematic Literature Review

2019

Part 9: Learning and Education; International audience; E-Learning systems are receiving ever increasing attention in, academia, businesses as well as in public administrations. Managers and employee who need efficient forms of training as well as learning flow within the organization, do not have to gather in a place at the same time, or to travel far away for attending courses. Contemporary affordances of e-learning systems allow them to perform different jobs or tasks for training courses according to their own scheduling, as well as collaborate and share knowledge and experiences that results rich learning flow within the organization. The purpose of this article is to provide a systema…

Literature reviewKnowledge managementComputer sciencebusiness.industryE-learning (theory)05 social sciencesBig dataLearning analyticsOrganizational learning050301 educationPersonalized learningE-learningVDP::Samfunnsvitenskap: 200::Pedagogiske fag: 280Learning environments[INFO.INFO-NI]Computer Science [cs]/Networking and Internet Architecture [cs.NI]Empirical researchSystematic reviewCategorization0502 economics and businessOrganizational learning[INFO]Computer Science [cs]business0503 education050203 business & management
researchProduct

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis

2019

Background: Efficient personalized therapy paradigms are needed to modify the disease course and halt gray (GM) and white matter (WM) damage in patients with multiple sclerosis (MS). Presently, promising disease-modifying drugs show impressive efficiency, however, tailored markers of therapy responses are required. Here, we aimed to detect in a real-world setting patients with a more favorable brain network response and immune cell dynamics upon dimethyl fumarate (DMF) treatment. Methods: In a cohort of 78 MS patients we identified two thoroughly matched groups, based on age, disease duration, disability status and lesion volume, receiving DMF (n = 42) and NAT (n = 36) and followed them ove…

Male0301 basic medicineDimethyl FumarateCD8-Positive T-Lymphocytesmultiple sclerosisGastroenterologychemistry.chemical_compound0302 clinical medicineImmunology and AllergyMedicineLongitudinal StudiesGray MatterOriginal ResearchAged 80 and overCerebral CortexDimethyl fumaratemedicine.diagnostic_testMiddle AgedWhite Mattermedicine.anatomical_structureCohortFemaleAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialtyImmunologyFlow cytometryWhite matter03 medical and health sciencesImmune systemAtrophystructural integrityInternal medicineHumansImmunologic FactorsAgedpersonalized therapybusiness.industryMultiple sclerosismedicine.diseasegray matter networksimmunocellular response030104 developmental biologywhite matter networkschemistryNerve Netbusinesslcsh:RC581-607CD8030215 immunologyFrontiers in Immunology
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Influence of Prebiotic Fructans on Retronasal Aroma from Elderly Individuals

2021

This study investigates for the first time the role of fructans with prebiotic effects (oligofructose and inulin) on retronasal aroma among elderly individuals. The impact of oligofructose (20% w/w) on retronasal aroma release was investigated using proton transfer reaction-mass spectrometry (PTR-MS) after 73 elderly individuals consumed aqueous solutions aromatized with five aroma compounds (pentan-2-one, nonan-2-one, hexan-2,3-dione, octanal and linalool). The influence of oligofructose and inulin (10% w/w) on the perceived intensity (n = 26) of two aroma descriptors (butter and floral) was also studied together with the possibility of a dumping effect on aroma evaluation due to the sweet…

Male030309 nutrition & dieteticsmedicine.medical_treatmentOligosaccharidesPharmaceutical ScienceOrganic chemistryAnalytical Chemistrychemistry.chemical_compoundpersonalized dietsQD241-441LinaloolDrug Discoveryin vivo aroma releaseFood sciencedumping effect2. Zero hunger0303 health sciencesbiology04 agricultural and veterinary sciencesSweetness040401 food scienceChemistry (miscellaneous)Molecular MedicineFemaleFibre contentInulinsweetness perceptionaroma perceptionFlowersNoseArticle03 medical and health sciences0404 agricultural biotechnologyFructanmedicineHumans[CHIM]Chemical Sciences[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPhysical and Theoretical ChemistryAromaAgedPrebioticprebiotic fibresbiology.organism_classificationPTR-MSFructansPrebioticsOctanalchemistryOdorantsButter[SDV.AEN]Life Sciences [q-bio]/Food and NutritionMolecules
researchProduct

The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper

2019

BACKGROUND AND PURPOSES: To describe current practice in the management of rectal cancer, to identify uncertainties that usually arise in the multidisciplinary team (MDT)'s discussions ('grey zones') and propose next generation studies which may provide answers to them. MATERIALS AND METHODS: A questionnaire on the areas of controversy in managing T2, T3 and T4 rectal cancer was drawn up and distributed to the Rectal-Assisi Think Tank Meeting (ATTM) Expert European Board. Less than 70% agreement on a treatment option was indicated as uncertainty and selected as a 'grey zone'. Topics with large disagreement were selected by the task force group for discussion at the Rectal-ATTM. RESULTS: The…

MaleBest practice guidelinesColorectal cancermedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEMedical Oncology030218 nuclear medicine & medical imagingCOLORECTAL-CANCER0302 clinical medicineADJUVANT CHEMOTHERAPYRectal cancerNeoadjuvant therapyRandomized Controlled Trials as TopicSettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIARadiology Nuclear Medicine & Medical ImagingChemoradiotherapyCytoreduction Surgical ProceduresHematologyMiddle AgedOPEN-LABELTotal mesorectal excisionNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleLife Sciences & Biomedicinemedicine.medical_specialtyOrgan preservationLOCAL RECURRENCEAreas of uncertaintiesCOURSE PREOPERATIVE RADIOTHERAPYAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicine;03 medical and health sciencesLow rectal cancerRADIATION-THERAPYmedicineHumansRadiology Nuclear Medicine and imagingMedical physicsEXTRAMURAL VASCULAR INVASIONNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTask forceAreas of uncertainties; Best practice guidelines; Colorectal cancer; Organ preservation; Personalized medicineTOTAL MESORECTAL EXCISIONRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseColorectal cancerPersonalized medicineClinical trialRadiation therapyPersonalized medicinebusiness
researchProduct

Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

2013

Several pathologies affect human prostate, such as prostate cancer (PC), which is the most common non-skin malignant cancer in Western male populations. A complex interaction between genetic and environmental factors (i.e. infectious agents, dietary carcinogens) and hormonal imbalances has been reported to have a fundamental role in PC pathophysiology by evoking chronic inflammation. Thus, chronic inflammation drives prostate carcinogenesis and neoplastic progression. No adequate biomarkers exist until now to guide PC prognosis and treatment. Accordingly, the research has particularly focused its attention on genetic variants in genes, codifying molecules of signaling innate immune/inflamma…

MaleCancer ResearchSNPBioinformaticsTranslational Research BiomedicalProstate cancersex steroid and inflammatory networkRisk FactorsmedicineSettore MED/05 - Patologia ClinicaHumansGenetic Predisposition to DiseaseGenetic riskPrecision MedicineGonadal Steroid HormonesMolecular BiologyAllelesSettore MED/04 - Patologia GeneraleInflammationPolymorphism Geneticbusiness.industryrisk profileCancerProstatic NeoplasmsTranslation (biology)prostate cancermedicine.diseasePathophysiologypersonalized PC medicineCell Transformation NeoplasticImmunologygenetic biomarkerDisease ProgressionMolecular MedicinebusinessSignal TransductionCancer gene therapy
researchProduct

Personalized Symptom Goals and Patient Global Impression on Clinical Changes in Advanced Cancer Patients.

2018

Abstract Background The aim of this study was to assess the patients’ global impression (PGI) after symptom management, as well as the achievement of personalized symptom goals (PSG). The secondary outcome was to assess related factors. Subjects, Materials, and Methods Advanced cancer patients admitted to palliative care units rated symptom intensity by using the Edmonton Symptom Assessment Score (ESAS) at admission and then after 1 week. For each symptom, patient-reported PGI and PSG, as well as the rate of PSG response, were evaluated. Results Eight hundred seventy-six patients were taken into consideration for this study. A mean of 1.71–2.16 points was necessary to perceive a bit better …

MaleCancer Researchmedicine.medical_specialtyMultivariate analysisPalliative careSymptom assessmentGlobal impression of change03 medical and health sciences0302 clinical medicineIntervention (counseling)Advanced cancerNeoplasmsmedicineOdd ratioHumans030212 general & internal medicineRelated factorsSymptom managementbusiness.industryAdvanced cancer; Global impression of change; Palliative care; Personalized symptom goal; Symptom assessmentAdvanced cancerOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisPersonalized symptom goalPhysical therapyPalliative careFemaleSymptom AssessmentbusinessThe oncologist
researchProduct